Assessment of the risk of malignancy in Bethesda III thyroid nodules : a comprehensive review
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
The increasing prevalence of thyroid cancer emphasizes the need for a thorough assessment of risk of malignancy in Bethesda III nodules. Various methods ranging commercial platforms of molecular genetic testing (including Afirma® GEC, Afirma® GSC, ThyroSeq® V3, RosettaGX®, ThyGeNEXT®/ThyraMIR®, ThyroidPRINT®) to radionuclide scans and ultrasonography have been investigated to provide a more nuanced comprehension of risk estimation. The integration of molecular studies and imaging techniques into clinical practice may provide clinicians with improved and personalized risk assessment. This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Endocrine - (2024) vom: 28. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rao, Karthik Nagaraja [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Artificial intelligence |
|---|
| Anmerkungen: |
Date Revised 28.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s12020-024-03737-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369063007 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369063007 | ||
| 003 | DE-627 | ||
| 005 | 20240229171929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12020-024-03737-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM369063007 | ||
| 035 | |a (NLM)38416380 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rao, Karthik Nagaraja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of the risk of malignancy in Bethesda III thyroid nodules |b a comprehensive review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a The increasing prevalence of thyroid cancer emphasizes the need for a thorough assessment of risk of malignancy in Bethesda III nodules. Various methods ranging commercial platforms of molecular genetic testing (including Afirma® GEC, Afirma® GSC, ThyroSeq® V3, RosettaGX®, ThyGeNEXT®/ThyraMIR®, ThyroidPRINT®) to radionuclide scans and ultrasonography have been investigated to provide a more nuanced comprehension of risk estimation. The integration of molecular studies and imaging techniques into clinical practice may provide clinicians with improved and personalized risk assessment. This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Artificial intelligence | |
| 650 | 4 | |a Bethesda system | |
| 650 | 4 | |a Molecular testing | |
| 650 | 4 | |a Risk assessment | |
| 650 | 4 | |a Thyroid neoplasms | |
| 700 | 1 | |a Randolph, Gregory W |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Zafereo, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Coca-Pelaz, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Dange, Prajwal |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigo, Juan Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Stenman, Göran |e verfasserin |4 aut | |
| 700 | 1 | |a de Keizer, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Nixon, Iain |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Shriyash |e verfasserin |4 aut | |
| 700 | 1 | |a Leboulleux, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Mäkitie, Antti A |e verfasserin |4 aut | |
| 700 | 1 | |a Agaimy, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Lester |e verfasserin |4 aut | |
| 700 | 1 | |a Ferlito, Alfio |e verfasserin |4 aut | |
| 700 | 0 | |a This paper was written by members and invitees of the International Head and Neck Scientific Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine |d 1995 |g (2024) vom: 28. Feb. |w (DE-627)NLM091795540 |x 1559-0100 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:28 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12020-024-03737-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 28 |c 02 | ||